¹⁷⁷Lu-rhPSMA-10.1 — Investigational Agent
Radiopharmaceutical · Phase 1/2 · Blue Earth Therapeutics
Mechanism of Action
A radiohybrid PSMA-targeted ligand labeled with the beta-emitter lutetium-177. It binds prostate-specific membrane antigen on prostate cancer cells and delivers targeted beta radiation to induce DNA double-strand breaks and cell death.
Investigational Indications
- Metastatic castration-resistant prostate cancer